Management

Kevin D. Lustig PhD, CEO and President

Kevin co-founded the Assay Depot in 2006. His last position was co-founder, first employee and research director at Kalypsys, a biopharmaceutical company that has raised over $300 million and has multiple drug candidates in the clinic. Prior to Kalypsys, Kevin was a research director at Tularik, a biopharmaceutical company that was purchased by Amgen for more than $2.5 billion. He carried out postdoctoral work at Harvard Medical School after receiving a PhD degree from Mark Kirschner's laboratory at the University of California, San Francisco (UCSF). Kevin received an A.B. degree magna cum laude from Cornell University's College of Arts and Sciences in 1985.

Andrew B. Martin PhD, Chief Operating Officer

Andy co-founded the Assay Depot in 2006. His last position was head of informatics at Kalypsys, where he led efforts to build state of the art data analysis, data storage and data mining tools for drug profiling assays used during each stage of the drug discovery process. He received a PhD degree in Chemistry from Peter Schultz's laboratory at the University of California, Berkeley. While at Berkeley and, subsequently, the Scripps Research Institute (TSRI), Andy's research focused on macromolecular conformational dynamics using single-molecule microscopy and dual, site-specific labeling methodologies. Andy received a B.A. degree magna cum laude in chemistry from Carleton College in 1996.

Christopher L. Petersen, Chief Information Officer

Chris joined the Assay Depot in February 2007. His last position was head of software development at Kalypsys, where he led efforts to design and develop custom software tools that improve drug discovery efficiency. Prior to Kalypsys, he was director of engineering at Learning Framework where he oversaw development of their flagship product, the Socrates Learning Performance Management System. He has led software development teams in industries ranging from streaming video to customer management. Chris received a B.S. degree in Computer Science in 1999 from Worcester Polytechnic Institute, where he received the Provost's award for work in evolutionary programming and genetic algorithms.

Charles R. Dowding PhD, Vice President of Research

Charles joined the Assay Depot in November 2007. His last position was head of the Radiation Countermeasure program at Hollis-Eden, a biopharmaceutical company that raised ~$70 million to support development of a small molecule treatment for acute radiation syndrome. Prior to Hollis-Eden, Charles was Director of Cell Process Development at SyStemix Inc, a biotechnology company that was purchased by Novartis for ~$600 million. He carried out postdoctoral work at the University of British Columbia and Quadra Logic Technologies in Vancouver, Canada after receiving a PhD degree from John Goldman's laboratory at the University of London, UK. Charles received a First Class Honors degree in Applied Biology from the University of Salford, UK, in 1982.